ScholarWorks@Korea University: Son, Sang Wook

Detailed Information

Son, Sang Wook (손상욱)

Department of Biomedical Sciences

Research Area

Tel 031-412-5180
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Atopic dermatitis:5||psoriasis:5||Microarray:5||Keratinocyte:4||atopic dermatitis:4||Egr1:4||Skin sensitization:3||STAT3:3||Phototoxicity:3||Human skin equivalent model:3||Early growth response1:3||Keratinocytes:3||Chloroform:2||mitogenactivated protein kinase:2||Gene expression profiling:2||cigarette smoke:2||nanoparticles:2||Therapeutics:2||rice bran supercritical CO2 extract:2||Gene expression:2||Methylation:2||ERK:2||Administration:2||nanomaterials:2||hair growthpromoting activity:2||Skin irritation:2||ZnO:2||Skin penetration:2||Toluene:2||Xylene:2||Volatile organic compound:2||thymic stromal lymphopoietin:2||Cytotoxicity:2||silica nanoparticles:2||keratinocyte:2||ROS:2||IL33:2||stereoimage optical topometer:2||Skin:2||Guideline:2||Volatile organic compounds (VOCs):2||ClueGO:1||HIF1:1||IL17:1||Calcium gluconate:1||TRUE Test (R):1||Skin fibroblast:1||xylene:1||gene expression:1||treatment:1||epidemiology:1||clinical study:1||topical:1||Maintenance therapy:1||Seborrheic dermatitis:1||Tacrolimus ointment:1||mTOR:1||subchronic toxicity:1||consumer characteristics:1||consumers:1||Acquired progressive lymphangioma:1||acne:1||Hypoxiainducible factor1 alpha:1||INSULINRESISTANCE:1||EARLYONSET:1||PREVALENCE:1||global assessment scale:1||vitiligo:1||skin ageing:1||3D EpiDerm™ model (EPI200):1||Cigarette smoking:1||Cytokines:1||Fas:1||microangiography:1||Cancer marker:1||Chemoimmunotherapy:1||Semipermanent tattoo:1||Lipliner tattoo:1||synchrotron:1||phase contrast Xray microscope:1||basal cell carcinoma:1||Dermatofibroma:1||Epidermis:1||Knockout mouse:1||Asian population:1||RIP4:1||Signal transducer and activator of transcription 3:1||Korean standard series:1||apoptosis:1||toluene:1||Skin barrier:1||interleukin33:1||Monocytes:1||Macrophages:1||Nanoparticle:1||toxicity:1||no observed adverse effect level:1||household income:1||psoriasin:1||APL:1||Ultraviolet B:1||Vascular endothelial growth factor:1||Nanotoxicity:1||CARDIOVASCULAR RISKFACTORS:1||MYOCARDIALINFARCTION:1||repigmentation percentage:1||Bioengineering methods:1||Absorption:1||Human skin fibroblasts:1||Toxicity:1||Irritation:1||NK inhibitory receptors:1||cDNA microarray:1||Homogeneous sensing probe:1||Bee sting:1||Lipoma:1||Chronic hand eczema:1||epigenetic:1||ustekinumab:1||ZnONPs:1||CCL20:1||concordance:1||AKT:1||ethylbenzene:1||methylation:1||microarray:1||Nanoparticles:1||AD:1||opportunistic infections:1||1 alpha,25dihydroxyviamin D3:1||Reactive oxygen species:1||IL17A:1||fractional Er:glass:1||face:1||Nonmelanoma skin cancer:1||Silica:1||skin penetration:1||MALEPATTERN BALDNESS:1||excimer laser:1||Polystyrene:1||Mohs surgery:1||Pigmentation:1||Subclinical infiltration:1||Serum IgE:1||Tolllike receptor:1||Stratum corneum:1||Bone invasion:1||Lymph node metastasis:1||zebrafish:1||GMCSF:1||Republic of Korea:1||Systemic treatment:1||registry:1||Wound healing:1||Extracellular signalregulated kinase:1||Tacrolimus:1||IQ (R) Chamber:1||Behavior:1||prevention:1||mycoses:1||DNA methylation profiling:1||zinc oxide:1||Silver nanoparticles:1||autologous fat injection:1||surface charge:1||COMMUNITYBASED SURVEY:1||digital image analysis:1||TiO2:1||Skin aging:1||NOD2:1||NFkB:1||NKG2A:1||Interferonalpha2a:1||Cancer drugs:1||bioengineering methods:1||image analysis:1||severity psoriasis:1||Recurrent:1||Cutaneous horn:1||loxP:1||Consensus:1||Urban particulate matter:1||Human skin equivalent:1||Hydrofluoric acid:1||patch test:1||HSEM:1||Knowledge:1||Surveys and questionnaires:1||Timedependent exposure:1||dermal route:1||polyelectrolytes:1||Alopecia areata:1||HAIR LOSS:1||Acral lentiginous melanoma:1||Basal cell carcinoma:1||SiO2 nanoparticles:1||TNF alpha:1||Cutaneous:1||Melanoma:1||Surfaceenhanced Raman scattering:1||Cellular imaging:1||Foreign body granuloma:1||autoregulation:1||protein corona:1||Natural extracts:1||quantum dots:1||Awareness:1||exposure time:1||FLG:1||Biomarker:1||Environmental Risk Assessment:1||early growth response protein 1:1||dermatomycoses:1||oral:1||Dermatitis:1||Korea:1||keratinocytes:1||necribiosis:1||early growth response1:1||Type II TGFbeta receptor:1||Blau syndrome:1||Umbilicus:1||natural killer cells:1||NK activating receptors:1||intravital imaging:1||quantum dot:1||PCR array:1||PASI:1||Congenital smooth muscle hamartoma:1||Cre:1||Consensus guidelines:1||synapse:1||Early growth response protein 1:1||Psoriasis:1||Topical administration:1||Cysteinerich 61:1||Segmentation:1||Ethylbenzene:1||alopecia:1||candidiasis:1||Zinc Oxide:1||comparative analysis:1||survey:1||lipoidica:1||Lymphangioma:1||dystrophic calcification:1||human skin equivalent model:1||gold nanorods:1||Corticosteroid:1||MEN:1||cysteinerich 61:1||Dermoscopy:1||Gastric mucosa:1||Quantum dots:1||Nanosilica:1||Hollow gold nanosphere:1||Hydrogel:1||tumor necrosis factor alpha:1||EGR1:1||visual scoring system:1||Human tail론피부 평활근 과오종(smooth muscle hamartoma)은 진피 내 평활근의 양성 증식이 선천적 또는 드물게 후천적으로 발생하는 질환으로서1:1||1923년 Stokes2에 의해 처음 기술된 질환이다. 병변은 과색소 침착이나 다모성의 병변이 판이나 반의 형태를 나타낸다.:1||Therapeutics:1||BMP6:1||Claudin 1:1||Thymic stromal lymphopoietin:1||Eczema:1||atopic eczema:1||fungi:1||Ethylbenzene (EB):1||TREM1:1||particle size:1||90day oral dose toxicity:1||dermal exposure:1||questionnaire survey:1||experts:1||filaggrin:1||in vivo:1||Human keratinocytes:1||ZnO nanoparticles:1||Panax ginseng:1||CORONARYHEARTDISEASE:1||area:1||Korean red ginseng:1||Heterotopia:1||Tape stripping method:1||CD94:1||Quantum dot:1||Pseudolymphoma:1||Nodular fasciitis:1||Floxed:1||combined exposure:1||long noncoding RNA:1||longterm depression:1||observational study:1||

STATISTICS: Total View :6,966,342; Today View :1,836

RSS_1.0 RSS_2.0 ATOM_1.0

145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE